{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:32:41Z","timestamp":1793514761465,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ESCEO","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00198-019-05104-5","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T22:03:02Z","timestamp":1566856982000},"page":"2155-2165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)"],"prefix":"10.1007","volume":"30","author":[{"given":"M.","family":"Hiligsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vrijens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Biver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Burlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gasparik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Halbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tuzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vlaskovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"1","key":"5104_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344","journal-title":"Osteoporos Int"},{"issue":"5","key":"5104_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jval.2012.02.001","volume":"15","author":"M Hiligsmann","year":"2012","unstructured":"Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15(5):604\u2013612","journal-title":"Value Health"},{"issue":"12","key":"5104_CR3","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res 30(12):2179\u20132187","journal-title":"J Bone Miner Res"},{"issue":"7","key":"5104_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","volume":"28","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28(7):2023\u20132034","journal-title":"Osteoporos Int"},{"key":"5104_CR5","volume-title":"Adherence to long-term therapies: evidence for action","year":"2003","unstructured":"Sabate E (ed) (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva"},{"issue":"1","key":"5104_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11914-006-0011-8","volume":"4","author":"DT Gold","year":"2006","unstructured":"Gold DT, Silverman S (2006) Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 4(1):21\u201327","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"5104_CR7","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00198-013-2364-z","volume":"24","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24(12):2907\u20132918","journal-title":"Osteoporos Int"},{"key":"5104_CR8","unstructured":"Cornelissen D, et al. Interventions to improve osteoporosis medication adherence and persistence: an updated systematic review and literature appraisal In submission"},{"issue":"5","key":"5104_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691\u2013705","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5104_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/M18-0543","volume":"169","author":"S De Geest","year":"2018","unstructured":"De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB et al (2018) ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med 169(1):30\u201335","journal-title":"Ann Intern Med"},{"issue":"10","key":"5104_CR11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00198-007-0410-4","volume":"18","author":"F Lekkerkerker","year":"2007","unstructured":"Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY, Group for the Respect of Ethics and Excellence in Science (GREES) (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18(10):1311\u20131317","journal-title":"Osteoporos Int"},{"issue":"12","key":"5104_CR12","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29(12):2623\u20132637","journal-title":"Osteoporos Int"},{"issue":"4","key":"5104_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","volume":"25","author":"MA Fischer","year":"2010","unstructured":"Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, Weissman JS (2010) Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 25(4):284\u2013290","journal-title":"J Gen Intern Med"},{"issue":"9","key":"5104_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s00198-013-2326-5","volume":"24","author":"K Reynolds","year":"2013","unstructured":"Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, Gold DT, Vansomphone SS, Wei R, O\u2019Malley CD (2013) Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 24(9):2509\u20132517","journal-title":"Osteoporos Int"},{"issue":"6","key":"5104_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1586\/erp.10.76","volume":"10","author":"V Rabenda","year":"2010","unstructured":"Rabenda V, Reginster JY (2010) Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res 10(6):677\u2013689","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"14","key":"5104_CR16","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1517\/14656560903140533","volume":"10","author":"V Rabenda","year":"2009","unstructured":"Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10(14):2303\u20132315","journal-title":"Expert Opin Pharmacother"},{"key":"5104_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","volume":"6","author":"O Strom","year":"2011","unstructured":"Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59\u2013155","journal-title":"Arch Osteoporos"},{"issue":"2","key":"5104_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433\u2013443","journal-title":"Osteoporos Int"},{"key":"5104_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","volume":"52","author":"TF Blaschke","year":"2012","unstructured":"Blaschke TF, Osterberg L, Vrijens B, Urquhart J (2012) Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 52:275\u2013301","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"5104_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19(6):811\u2013818","journal-title":"Osteoporos Int"},{"issue":"5","key":"5104_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00774-013-0440-2","volume":"31","author":"JFM van Boven","year":"2013","unstructured":"van Boven JFM, de Boer PT, Postma MJ, Vegter S (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 31(5):562\u2013570","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"5104_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00198-008-0651-x","volume":"20","author":"C Roerholt","year":"2009","unstructured":"Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20(2):299\u2013307","journal-title":"Osteoporos Int"},{"issue":"3","key":"5104_CR23","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00198-015-3378-5","volume":"27","author":"L Jacob","year":"2016","unstructured":"Jacob L, Dreher M, Kostev K, Hadji P (2016) Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int 27(3):963\u2013969","journal-title":"Osteoporos Int"},{"key":"5104_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137","journal-title":"Arch Osteoporos"},{"issue":"9","key":"5104_CR25","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/jbmr.2301","volume":"29","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29(9):1926\u20131928","journal-title":"J Bone Miner Res"},{"key":"5104_CR26","doi-asserted-by":"crossref","unstructured":"Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol. 2012;52:275\u2212+","DOI":"10.1146\/annurev-pharmtox-011711-113247"},{"key":"5104_CR27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/IJGM.S36944","volume":"6","author":"A Balasubramanian","year":"2013","unstructured":"Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839\u2013848","journal-title":"Int J Gen Med"},{"issue":"12","key":"5104_CR28","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.clinthera.2011.10.021","volume":"33","author":"SW Wade","year":"2011","unstructured":"Wade SW, Satram-Hoang S, Nadkar A, Macarios D, Tosteson AN (2011) Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy. Clin Ther 33(12):2006\u20132015","journal-title":"Clin Ther"},{"key":"5104_CR29","doi-asserted-by":"crossref","unstructured":"Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3\u2013S13","DOI":"10.1016\/j.amjmed.2008.12.002"},{"issue":"4","key":"5104_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571\u2013581","journal-title":"Value Health"},{"issue":"11","key":"5104_CR31","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943\u20131951","journal-title":"Osteoporos Int"},{"issue":"12","key":"5104_CR32","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00198-014-2810-6","volume":"25","author":"I Kyvernitakis","year":"2014","unstructured":"Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 25(12):2721\u20132728","journal-title":"Osteoporos Int"},{"issue":"10","key":"5104_CR33","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","volume":"26","author":"P Hadji","year":"2015","unstructured":"Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, M\u00f6ller G, Kalouche-Khalil L, Fahrleitner-Pammer A (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26(10):2479\u20132489","journal-title":"Osteoporos Int"},{"issue":"9","key":"5104_CR34","doi-asserted-by":"publisher","first-page":"824","DOI":"10.18553\/jmcp.2015.21.9.824","volume":"21","author":"LI Cheng","year":"2015","unstructured":"Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS (2015) Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Ph 21(9):824\u2013U322","journal-title":"J Manag Care Spec Ph"},{"issue":"5","key":"5104_CR35","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28(5):1723\u20131732","journal-title":"Osteoporos Int"},{"issue":"9","key":"5104_CR36","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00198-011-1881-x","volume":"23","author":"YK Lee","year":"2012","unstructured":"Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23(9):2329\u20132333","journal-title":"Osteoporos Int"},{"issue":"2","key":"5104_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00296-009-0940-5","volume":"30","author":"JD Ringe","year":"2009","unstructured":"Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30(2):213\u2013221","journal-title":"Rheumatol Int"},{"issue":"1","key":"5104_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23(1):213\u2013221","journal-title":"Osteoporos Int"},{"issue":"3","key":"5104_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","volume":"86","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202\u2013210","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"5104_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.healthpol.2010.01.014","volume":"96","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2):170\u2013177","journal-title":"Health Policy"},{"issue":"11","key":"5104_CR41","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1359\/jbmr.090506","volume":"24","author":"MD Danese","year":"2009","unstructured":"Danese MD, Badamgarav E, Bauer DC (2009) Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 24(11):1819\u20131826","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5104_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Strom","year":"2009","unstructured":"Strom O, Borgstrom F, Kanis J, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23\u201334","journal-title":"Osteoporos Int"},{"issue":"2","key":"5104_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/erp.12.8","volume":"12","author":"M Hiligsmann","year":"2012","unstructured":"Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12(2):159\u2013166","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"5104_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, al-Daghri N, Bruy\u00e8re O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30(1):45\u201357","journal-title":"Osteoporos Int"},{"issue":"2","key":"5104_CR45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433\u2013443","journal-title":"Osteoporos Int"},{"key":"5104_CR46","doi-asserted-by":"crossref","unstructured":"Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207-","DOI":"10.1111\/j.1547-5069.2003.tb00001.x"},{"key":"5104_CR47","doi-asserted-by":"crossref","unstructured":"Kardas P, Lewek P, Matyjaszczyk M (2013) Determinants of patient adherence: a review of systematic reviews. Front Pharmacol 4","DOI":"10.3389\/fphar.2013.00091"},{"issue":"3","key":"5104_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775\u2013780","journal-title":"Osteoporos Int"},{"issue":"1","key":"5104_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00198-013-2430-6","volume":"25","author":"DE Beaton","year":"2014","unstructured":"Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JE et al (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy\u2019s fracture clinic screening program. Osteoporos Int 25(1):289\u2013296","journal-title":"Osteoporos Int"},{"issue":"9","key":"5104_CR50","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00198-014-2728-z","volume":"25","author":"SR Majumdar","year":"2014","unstructured":"Majumdar SR, McAlister FA, Johnson JA, Weir DL, Bellerose D, Hanley DA et al (2014) Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int 25(9):2173\u20132179","journal-title":"Osteoporos Int"},{"key":"5104_CR51","first-page":"w14451","volume":"147","author":"S Morell","year":"2017","unstructured":"Morell S, Hemmeler C, Amsler F, Gross T (2017) Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture - a Swiss trauma center secondary prevention project. Swiss Med Wkly 147:w14451","journal-title":"Swiss Med Wkly"},{"key":"5104_CR52","first-page":"821","volume":"9","author":"J Yu","year":"2015","unstructured":"Yu J, Brenneman SK, Sazonov V, Modi A (2015) Reasons for not initiating osteoporosis therapy among a managed care population. Patient Prefer Adherence 9:821\u2013830","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"5104_CR53","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00198-013-2283-z","volume":"24","author":"L Tafaro","year":"2013","unstructured":"Tafaro L, Nati G, Leoni E, Baldini R, Cattaruzza MS, Mei M, Falaschi P (2013) Adherence to anti-osteoporotic therapies: role and determinants of \u201cspot therapy\u201d. Osteoporos Int 24(8):2319\u20132323","journal-title":"Osteoporos Int"},{"issue":"2","key":"5104_CR54","first-page":"72","volume":"34","author":"MD Iversen","year":"2011","unstructured":"Iversen MD, Vora RR, Servi A, Solomon DH (2011) Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 34(2):72\u201381","journal-title":"J Geriatr Phys Ther"},{"issue":"1","key":"5104_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","volume":"24","author":"A Papaioannou","year":"2007","unstructured":"Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24(1):37\u201355","journal-title":"Drugs Aging"},{"issue":"1","key":"5104_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22(1):21\u201326","journal-title":"Osteoporos Int"},{"issue":"3","key":"5104_CR57","first-page":"394","volume":"54","author":"E Lau","year":"2008","unstructured":"Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka AM, Burns S, Nair K, Pathak A (2008) Patients\u2019 adherence to osteoporosis therapy - exploring the perceptions of postmenopausal women. Can Fam Physician 54(3):394\u2013402","journal-title":"Can Fam Physician"},{"issue":"7","key":"5104_CR58","first-page":"417","volume":"15","author":"ADH Shu","year":"2009","unstructured":"Shu ADH, Stedman MR, Polinski JM, Jan SA, Patel M, Truppo C, Breiner L, Chen YY, Weiss TW, Solomon DH (2009) Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 15(7):417\u2013424","journal-title":"Am J Manag Care"},{"issue":"6","key":"5104_CR59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archinternmed.2011.1977","volume":"172","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, Iversen MD, Avorn J, Gleeson T, Brookhart MA, Patrick AR, Rekedal L, Shrank WH, Lii J, Losina E, Katz JN (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172(6):477\u2013483","journal-title":"Arch Intern Med"},{"issue":"4","key":"5104_CR60","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1210\/jc.2006-1526","volume":"92","author":"PD Delmas","year":"2007","unstructured":"Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92(4):1296\u20131304","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5104_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/europace\/euu311","volume":"17","author":"B Vrijens","year":"2015","unstructured":"Vrijens B, Heidbuchel H (2015) Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 17(4):514\u2013523","journal-title":"Europace"},{"key":"5104_CR62","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/bcp.13905","volume":"85","author":"B Vrijens","year":"2019","unstructured":"Vrijens B (2019) A Six Sigma framework to successfully manage medication adherence. Br J Clin Pharmacol 85:1661\u20131663","journal-title":"Br J Clin Pharmacol"},{"key":"5104_CR63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ypmed.2016.07.006","volume":"90","author":"JA Rash","year":"2016","unstructured":"Rash JA, Campbell DJT, Tonelli M, Campbell TS (2016) A systematic review of interventions to improve adherence to statin medication: what do we know about what works? Prev Med 90:155\u2013169","journal-title":"Prev Med"},{"issue":"2","key":"5104_CR64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11096-012-9607-5","volume":"34","author":"J van Dalem","year":"2012","unstructured":"van Dalem J, Krass I, Aslani P (2012) Interventions promoting adherence to cardiovascular medicines. Int J Clin Pharm-Net 34(2):295\u2013311","journal-title":"Int J Clin Pharm-Net"},{"issue":"9","key":"5104_CR65","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1742-1241.2011.02746.x","volume":"65","author":"WW Chong","year":"2011","unstructured":"Chong WW, Aslani P, Chen TF (2011) Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract 65(9):954\u2013975","journal-title":"Int J Clin Pract"},{"issue":"5","key":"5104_CR66","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00198-017-3953-z","volume":"28","author":"B Merle","year":"2017","unstructured":"Merle B, Chapurlat R, Vignot E, Thomas T, Haesebaert J, Schott AM (2017) Post-fracture care: do we need to educate patients rather than doctors? The PREVOST randomized controlled trial. Osteoporos Int 28(5):1549\u20131558","journal-title":"Osteoporos Int"},{"key":"5104_CR67","doi-asserted-by":"crossref","unstructured":"Seuffert P, Sagebien CA, McDonnell M, O\u2019Hara DA. Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos. 2016;11(1)","DOI":"10.1007\/s11657-016-0262-7"},{"key":"5104_CR68","doi-asserted-by":"crossref","unstructured":"Beaton DE, Mamdani M, Zheng H, Jaglal S, Cadarette SM, Bogoch ER, et al. Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program: an interrupted time series analysis. Medicine. 2017;96(48)","DOI":"10.1097\/MD.0000000000009012"},{"key":"5104_CR69","unstructured":"Parsons C, Harvey N, Shepstone L, Kanis J, Lenaghan E, Clarke S, et al. Systematic screening using Frax leads to increased use of, and adherence to, anti-osteoporosis medications: the Uk Scoop Trial. Osteoporosis Int. 2018;29:613-"},{"issue":"2","key":"5104_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pec.2010.03.010","volume":"81","author":"D Nielsen","year":"2010","unstructured":"Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K (2010) Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns 81(2):155\u2013160","journal-title":"Patient Educ Couns"},{"issue":"6","key":"5104_CR71","first-page":"1807","volume":"25","author":"AGG Stuurman-Bieze","year":"2014","unstructured":"Stuurman-Bieze AGG, Hiddink EG, van Boven JFM, Vegter S (2014) Proactive pharmaceutical care interventions decrease patients\u2019 nonadherence to osteoporosis medication. Osteoporos Int 25(6):1807\u20131812","journal-title":"Osteoporos Int"},{"issue":"3","key":"5104_CR72","first-page":"E81","volume":"7","author":"V Ducoulombier","year":"2015","unstructured":"Ducoulombier V, Luraschi H, Forzy G, Vandecandelaere M, Houvenagel E (2015) Contribution of phone follow-up to improved adherence to oral osteoporosis treatment. Am J Pharm Benefist 7(3):E81\u2013EE9","journal-title":"Am J Pharm Benefist"},{"issue":"3","key":"5104_CR73","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-018-04821-7","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY (2019) Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos Int 30(3):649\u2013658","journal-title":"Osteoporos Int"},{"issue":"1","key":"5104_CR74","first-page":"67","volume":"49","author":"A Oral","year":"2015","unstructured":"Oral A, Lorenc R, Investigators F-AS (2015) Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study. Acta Orthop Traumatol Turc 49(1):67\u201374","journal-title":"Acta Orthop Traumatol Turc"},{"issue":"9","key":"5104_CR75","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","volume":"366","author":"MJ Barry","year":"2012","unstructured":"Barry MJ, Edgman-Levitan S (2012) Shared decision making--pinnacle of patient-centered care. N Engl J Med 366(9):780\u2013781","journal-title":"N Engl J Med"},{"key":"5104_CR76","doi-asserted-by":"crossref","unstructured":"Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB et al (2017) Decision aids for people facing health treatment or screening decisions. Cochrane Db Syst Rev 4","DOI":"10.1002\/14651858.CD001431.pub5"},{"issue":"6","key":"5104_CR77","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjmed.2011.01.013","volume":"124","author":"VM Montori","year":"2011","unstructured":"Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA et al (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124(6):549\u2013556","journal-title":"Am J Med"},{"issue":"8","key":"5104_CR78","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s00198-016-3555-1","volume":"27","author":"M Hiligsmann","year":"2016","unstructured":"Hiligsmann M, Ronda G, van der Weijden T, Boonen A (2016) The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. Osteoporos Int 27(8):2489\u20132496","journal-title":"Osteoporos Int"},{"issue":"2","key":"5104_CR79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-016-3767-4","volume":"28","author":"AJ Smallwood","year":"2017","unstructured":"Smallwood AJ, Schapira MM, Fedders M, Neuner JM (2017) A pilot randomized controlled trial of a decision aid with tailored fracture risk tool delivered via a patient portal. Osteoporos Int 28(2):567\u2013576","journal-title":"Osteoporos Int"},{"issue":"4","key":"5104_CR80","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jocd.2010.06.005","volume":"13","author":"EM Lewiecki","year":"2010","unstructured":"Lewiecki EM (2010) Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom 13(4):335\u2013345","journal-title":"J Clin Densitom"},{"issue":"2","key":"5104_CR81","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00223-014-9869-0","volume":"95","author":"AI Gasparik","year":"2014","unstructured":"Gasparik AI (2014) Clinical setting influences patterns of interaction between osteoporosis patient and physician. Calcif Tissue Int 95(2):122\u2013124","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"5104_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40520-018-1098-3","volume":"31","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Pinto D, Dennison E, Al-Daghri N, Beaudart C, Branco J et al (2019) Patients\u2019 preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clin Exp Res 31(1):1\u20133","journal-title":"Aging Clin Exp Res"},{"issue":"7","key":"5104_CR83","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40520-019-01193-8","volume":"31","author":"M de Wit","year":"2019","unstructured":"de Wit M, Cooper C, Tugwell P, Bere N, Kirwan J, Conaghan PG et al (2019) Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 31(7):905\u2013915","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"5104_CR84","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s11914-018-0494-0","volume":"16","author":"S Silverman","year":"2018","unstructured":"Silverman S, Gold DT (2018) Medication decision-making in osteoporosis: can we explain why patients do not take their osteoporosis medications? Current Osteoporosis Reports 16(6):772\u2013774","journal-title":"Current Osteoporosis Reports"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05104-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T12:13:02Z","timestamp":1610885582000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["5104"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05104-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"13 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MLB has received honoraria from Amgen, Bruno Farmaceutici, Kyowa Kirin; academic grants and\/or speaker from Abiogen, Alexion, Amgen, Bruno, Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire and SPA; and consulting fees from Alexion, Bruno Farmaceutici, Kyowa Kirin, Servier and Shire.OB received grants research from Biophytis, IBSA, MEDA, Servier, SMB and consulting or lecture fees from Amgen, Biophytis, IBSA, MEDA, Servier, SMB, TRB Chemedica and UCB.BC has received Fees for occasional interventions as an expert or speaker for Amgen, Expanscience, Ferring, Lilly, Medtronic, MSD, Mylan, Novartis, Roche Diagnostics and UCB.CC has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestl\u00e9, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work.DC is funded by the Netherlands Organization for Health Research and Development (ZonMw), grant application number 848016001.ED has received honoraria from Pfizer and UCB.ADP has received consulting and speaker fees from Amgen, UCB, Eli Lilly, Roche and Gilead and own shares of Active Life Sci.JAK reports grants from Amgen, Eli Lilly and Radius Health and consulting fees from Theramex.PH has received consulting and speaker fees from Amgen, Dr. Kade\/Besin, Gedeon Richter, Elli Lilly, Meda\/Mylan, Novartis, Pfizer, Roche, Theramex and UCB and has given expert testimony on behalf of Novartis.RR has been speaker bureau or member of scientific advisory boards for Danone, Echolight, Effryx, Mylan, Nestl\u00e9, ObsEva, Pfizer, Radius Health, Sandoz and TEVA\/Theramex.TT reports personal fees for lectures and expertises from Abbvie, Amgen, Arrow, BMS, Chugai, Expanscience, Gilead, HAC-Pharma, LCA, Lilly, Medac, MSD, Pfizer, Theramex, Thuasne, TEVA and UCB and financial support or fees for research activities from Amgen, Bone Therapeutics, Chugai, HAC-Pharma, MSD, Novartis, Pfizer and UCB.JYR has received consulting fees or paid advisory boards from IBSA-GENEVRIER, Mylan, Radius Health, Pierre Fabre; lecture fees when speaking at the invitation of sponsor for IBSA-GENEVRIER, Mylan, CNIEL and Dairy Research Council; and grant support from industry (all through institution) from IBSA-GENEVRIER, Mylan, CNIEL and Radius Health.The other authors have no conflict of interest to declare relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}